Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00

Century Therapeutics, Inc. (NASDAQ:IPSC) has received an average rating of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.

IPSC has been the subject of a number of analyst reports. Piper Sandler reduced their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IPSC. State Street Corp grew its position in shares of Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after purchasing an additional 57,323 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Century Therapeutics in the third quarter valued at about $284,000. Barclays PLC grew its position in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after purchasing an additional 45,797 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Century Therapeutics by 3.5% in the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Century Therapeutics by 257.6% in the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after purchasing an additional 51,664 shares during the last quarter. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Stock Up 6.8 %

NASDAQ IPSC opened at $0.60 on Thursday. The stock has a market capitalization of $50.70 million, a PE ratio of -0.32 and a beta of 1.75. The company has a 50 day moving average price of $0.79 and a two-hundred day moving average price of $1.20. Century Therapeutics has a 12-month low of $0.55 and a 12-month high of $5.24.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.